Poisoning in Children 5: Rare and Dangerous Poisons

Total Page:16

File Type:pdf, Size:1020Kb

Poisoning in Children 5: Rare and Dangerous Poisons LEADING ARTICLE 407 Poisoning uptake and reducing hepatic gluconeo- Arch Dis Child: first published as 10.1136/adc.87.5.407 on 1 November 2002. Downloaded from ................................................................................... genesis. In overdose, it can produce significant gastrointestinal disturbance. In addition to hypoglycaemia, met- Poisoning in children 5: Rare and formin can induce a profound lactic acidosis.7 Serum electrolytes, lactate, and dangerous poisons bicarbonate should be monitored. Hy- poglycaemia should be treated with M Riordan, G Rylance, K Berry intravenous dextrose infusion. Asympto- matic patients should be observed for 12 ................................................................................... hours.1 β Acarbose inhibits glucosidases in the Management of children who have ingested blockers, intestine, preventing the digestion and digoxin, oral hypoglycaemics, organophosphates, carbon absorption of complex carbohydrates. monoxide, cyanide, isopropanol, ethylene glycol, methanol, Hypoglycaemia is unlikely but diarrhoea Ecstasy, LSD, cocaine, nicotine, and isoniazid may occur, particularly if patients receive carbohydrate rich foods following inges- tion. n the final paper in this series of Treatment in the first instance is with Repaglinide is a newer oral hypogly- articles on the management of poison- activated charcoal. Repeated doses caemic agent. It acts by stimulating ing, we deal with exposures to a should be considered.3 Blood pressure insulin release but has a very short dura- I 7 variety of rare, but potentially very and ECG monitoring are required. Elec- tion of action. Blood sugar should be dangerous, toxins. trolytes should be monitored frequently. checked and symptomatic children Hyperkalaemia should be corrected should receive oral glucose. Effects are β BLOCKERS using ion exchange resins, glucose and likely to be short lived. β Blockers competitively antagonise the insulin, or dialysis. Salbutamol and binding of catecholamines to β receptors. calcium infusions should be avoided ORGANOPHOSPHATES The effect of specific agents in overdose because of their potential to destabilise Organophosphates are found in insecti- depends on their receptor specificity, the myocardium. cides, sheep dip, and lice treatments. lipid solubility, partial agonist activity, Bradyarrhythmias may require treat- They produce irreversible acetylcho- and dose. ment with atropine or cardiac pacing. linesterase inhibition. Accumulation of Bradycardia and hypotension are the Tachyarrhythmias may respond to ligno- acetylcholine stimulates muscarinic re- 14 commonest signs of cardiovascular tox- caine, amiodarone, or phenytoin. There ceptors at parasympathetic postgangli- onic synapses. icity, but tachycardia and hypertension is an increased risk of inducing asystole Symptoms of organophosphate poi- can occur if a partial agonist is con- with cardioversion and this should be soning can be delayed for up to 24 hours sumed. Other signs of cardiovascular used only as a last resort. post-exposure. Symptoms, produced by toxicity include varying degrees of heart The use of digoxin antibodies should parasympathetic over stimulation, in- block, shock, and pulmonary oedema. be considered where patients are resist- clude increased secretions from salivary, Central effects can occur, particularly ant to supportive treatment or a very lacrimal, bronchial, and gastrointestinal with propanolol, and include lethargy, large amount of digoxin has been in- glands, increased peristaltic activity, http://adc.bmj.com/ hallucinations, and convulsions. Hy- gested (more than 300 µg/kg). bronchoconstriction, bradycardia and poglycaemia can also occur. Plasma digoxin concentrations can be hypotension, miosis, and loss of visual Asymptomatic children should receive determined six hours post-ingestion. acuity. Urinary and faecal incontinence activated charcoal. A period of 12 hours The upper end of the therapeutic range is occur secondary to loss of sphincter con- observation is advisable.1 Symptomatic 2 µg/l. A blood level above 15 µg/l usually trol. In severe cases, overwhelming tra- children require intensive monitoring. indicates severe toxicity. Levels between cheobronchial secretions can lead to res- Hypotension may respond to intra- these points should be interpreted with caution, as they do not correlate accu- piratory compromise. In large doses, venous fluids. In resistant cases, intra- on October 3, 2021 by guest. Protected copyright. µ rately with clinical severity. organophosphates produce muscle venous glucagon (50–150 g/kg in 5% stimulation followed by paralysis be- dextrose) is the treatment of choice. cause of a depolarising block. Hypergly- High dose glucagon stimulates myocar- ORAL HYPOGLYCAEMICS caemia and glycosuria without ketonu- dial adenylate cyclase directly, bypassing Sulphonylurea type drugs produce hy- β ria may also occur. receptors. Isoprenaline or cardiac pac- poglycaemia by depolarising pancreatic While organophosphates can be ab- ing may be required. Regular estimation β cells and increasing insulin release. sorbed via the skin, symptoms rarely of blood sugar is essential. Ingestion of a single tablet can produce result from acute exposure. Ingestion symptomatic hypoglycaemia in children. carries the highest risk of acute toxicity. DIGOXIN Activated charcoal should be adminis- Asymptomatic children should be ob- Digoxin is potentially extremely toxic in tered. Asymptomatic children should be served overnight. Symptomatic children overdose. Children with underlying car- observed overnight as effects can be require careful observation. Mild symp- diac disease are particularly at risk and delayed for up to 16 hours.5 Symptomatic toms can be treated with supportive should always receive treatment. Chil- children require intensive monitoring. therapy alone. Patients with cardiorespi- dren without a history of heart disease Hypoglycaemia should be treated with ratory compromise require intensive require treatment if they have ingested intravenous dextrose infusion. Resistant care. Atropine, often in very high dosage, more than 100 µg/kg body weight. hypoglycaemia may respond to sub- acts as an antidote—blocking mus- The toxic effects of digoxin include cutaneous injection of the somatostatin carinic receptors and preventing the nausea, vomiting, hypotension, hyperka- analogue, octreotide, which inhibits pan- excessive activity of acetylcholine. laemia, and a multitude of cardiac creatic insulin release.6 Patients not responding to treatment arrhythmias.2 Careful monitoring is es- Metformin, a biguanide, acts by in- with atropine should be treated with sential as patients can deteriorate sud- creasing glucose uptake into the pralidoxime. This drug reactivates inacti- denly. muscles, inhibiting its gastrointestinal vated acetylcholinesterase. Pralidoxime www.archdischild.com 408 LEADING ARTICLE Table 1 Antidotes for cyanide poisoning Arch Dis Child: first published as 10.1136/adc.87.5.407 on 1 November 2002. Downloaded from Order Antidote Dose Side effects Comments 1st line Amyl nitrite Crushable perles, vapour inhaled, Methaemoglobinaemia The mechanism of action of amyl nitrite is either directly or via a bag and Vasodilatation unclear but may relate to its action as a mask Headache vasodilator 1st line Sodium 412.5 mg/kg (1.65 ml/kg of Nausea Combines with CN to form thiocyanate; thiosulphate 25% solution), maximum 50ml, Vomiting this is non-toxic and excreted in the urine give over 10 minutes Muscle cramps Arthralgia 2nd line Sodium nitrite 0.33 ml/kg of 3% solution, Potentially fatal See amyl nitrite. For moderate to severe maximum 10 ml, over 4 minutes methaemoglobinaemia, avoid poisoning, do not use as prophylaxis excessive dose, keep metHb at about 20% 2nd line Dicobalt EDTA 4 mg/kg over 1 minute, followed In the absence of cyanide, cobalt Chelates cyanide and does not produce by 50 ml 50% dextrose toxicity can be severe metHb. For moderate to severe poisoning, Anaphylaxis do not use as prophylaxis is most effective as an antidote when as high a concentration of inspired both natural, for example, wool and silk; given within the first 24 hours post- oxygen as circumstances permit should and synthetic, for example, polyurethane ingestion. be commenced immediately. High con- and polyacrylnitrile. Synthetic polymers centrations of oxygen hasten the disso- are used extensively in domestic furnish- CARBON MONOXIDE ciation of COHb. ings. Cyanide and carbon monoxide poi- Carbon monoxide poisoning accounts The classical sign of “cherry red” lips soning frequently coexist. Symington et for the largest group of poisoning deaths and nail beds is unusual. Signs of cardio- al found that 4% of those dying in house among children.8 vascular or neurological toxicity should fires had potentially lethal cyanide Carbon monoxide (CO) is most fre- be carefully sought. There are often asso- levels.9 quently encountered as a product of ciated injuries, such as burns or smoke Cyanide binds to ferric iron (Fe3+)in incomplete combustion. The affinity of inhalation. the cytochrome a-a3 complex, inhibiting haemoglobin for carbon monoxide is 210 Blood should be taken for acid-base its action and blocking the final step in times its affinity for oxygen. Once bound balance, electrolytes, and muscle en- oxidative phosphorylation. Aerobic me- to haemoglobin, carbon monoxide disso- zymes. Metabolic acidosis is common tabolism is halted and carbohydrate ciates very slowly. In addition, the bind- and should not be over corrected,
Recommended publications
  • Cyanide Poisoning and How to Treat It Using CYANOKIT (Hydroxocobalamin for Injection) 5G
    Cyanide Poisoning and How to Treat It Using CYANOKIT (hydroxocobalamin for injection) 5g 1. CYANOKIT (single 5-g vial) [package insert]. Columbia, MD: Meridian Medical Technologies, Inc.; 2011. Please see Important Safety Information on slides 3-4 and full Prescribing Information for CYANOKIT starting on slide 33. CYANOKIT is a registered trademark of SERB Sarl, licensed by Meridian Medical Technologies, Inc., a Pfizer company. Copyright © 2015 Meridian Medical Technologies, Inc., a Pfizer company. All rights reserved. CYK783109-01 November/2015. Indication and Important Safety Information……………………………………………………………………………….………..…..3 . Identifying Cyanide Poisoning……………………………………………………………………………………………………………….…………….….5 . How CYANOKIT (hydroxocobalamin for injection) Works……………………………………………………………….12 . The Specifics of CYANOKIT…………………………………………………………………………………………………………………………….………17 . Administering CYANOKIT………………………………………………………………………………………………………………………………..……….21 . Storage and Disposal of CYANOKIT…................................................................................................................................26 . Grant Information for CYANOKIT……………………………………………………………………………………………………………………....30 . Full Prescribing Information………………………………………………………………………………………………….………………………………33 Please see Important Safety Information on slides 3-4 and full Prescribing Information for CYANOKIT starting on slide 33. CYANOKIT (hydroxocobalamin for injection) 5 g for intravenous infusion is indicated for the treatment of known or suspected cyanide poisoning.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Salbutamol CFC-Free Inhaler 100 micrograms per metered dose, pressurised inhalation, suspension 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One metered dose contains 100 micrograms of salbutamol (equivalent to 120 micrograms of salbutamol sulphate). This is equivalent to a delivered dose of 90 micrograms of salbutamol (equivalent to 108 micrograms of salbutamol sulphate). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation suspension Pressurised inhalation suspension supplied in an aluminium canister with a metering valve and a plastic actuator and dust cap. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Salbutamol CFC-Free Inhaler is indicated in adults, adolescents and children. For babies and children under 4 years of age, see sections 4.2 and 5.1. Salbutamol CFC-Free Inhaler is indicated for the relief and prevention of bronchial asthma and conditions associated with reversible airways obstruction. Salbutamol CFC-Free Inhaler can be used as relief medication in the management of mild, moderate or severe asthma, provided that its use does not delay the introduction and use of regular inhaled corticosteroid therapy, where necessary. 4.2 Posology and method of administration Salbutamol CFC-Free Inhaler is for oral inhalation use only. Posology Adults (including the elderly) and adolescents (children 12 years and over): For the relief of acute bronchospasm, one inhalation (100 micrograms) increasing to two inhalations (200 micrograms), if necessary. To prevent allergen- or exercise-induced symptoms, two inhalations (200 micrograms) should be taken 10-15 minutes before challenge. Maximum daily dose: two inhalations (200 micrograms) up to four times a day.
    [Show full text]
  • Supporting Information a Analysed Substances
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich)
    [Show full text]
  • Cassava Cyanide Diseases & Neurolathyrism Network Issue Number 20, December 2012
    Working together to eliminate cyanide poisoning, konzo, tropical ataxic neuropathy (TAN) and neurolathyrism Cassava Cyanide Diseases & Neurolathyrism Network (ISSN 1838-8817 (Print): ISSN 1838-8825 (Online) Issue Number 20, December 2012 Contents Historical Awareness of Neurolathyrism, Historical Awareness of Neurolathyrism, and Cassava Toxicity and Cassava Toxicity ................................... 1 Most people studying lathyrism are likely to Acute cyanide poisoning from cassava: is have training in bio-scientific methods or in social it still common? ........................................... 4 science, yet there are considerable gaps of thinking International conference on “Recent and practice between different disciplines, e.g. from plant biologists to historians of food in human Trends in Lathyrus sativus Research” cultures. There are different approaches to what is (Hyderabad, India, November 8-9, 2012). ... 6 considered ‘well-founded knowledge’, and how it Neurolathyrism in Bidar and Medak may be established. This paper recognises such districts of South India ................................ 7 differences, and their relevance to knowledge- Residual Cyanide content In Cassava development in neurolathyrism, with brief Product of India ............................................ 7 comparison of cassava (manioc) and its toxicity. It also considers why a broader approach to knowledge is important, and whether historical CCDNN Coordinators: knowledge can be made useful to people who face Prof Fernand Lambein increased food scarcity, and are ‘below the radar’ of Ghent University, Institute for plant Biotechnology government attention. Outreach (IPBO) Review articles in lathyrism often begin with a Proeftuinstraat 86 N1, B-9000 Ghent, Belgium Phone: +32 484 417 5005 glimpse of history, citing ancient texts where E-mail: [email protected] or Lathyrus sativus seems to appear, or [email protected] archaeological reports of seeds found from antiquity.
    [Show full text]
  • Prodrugs Design Based on Inter- and Intramolecular Chemical Processes
    Chem Biol Drug Des 2013; 82: 643–668 Review Prodrugs Design Based on Inter- and Intramolecular Chemical Processes Rafik Karaman1,2,* compound satisfies a number of preset criteria to start clinical development. The number of years it takes to intro- 1Bioorganic Chemistry Department, Faculty of Pharmacy, duce a drug to the pharmaceutical market is over 10 years Al-Quds University, P.O. Box 20002, Jerusalem, Palestine with a cost of more than $1 billion dollars (1,2). 2Department of Science, University of Basilicata, Via dell’Ateneo Lucano 10, 85100, Potenza, Italy Modifying the absorption, distribution, metabolism, and *Corresponding author: Rafik Karaman, elimination (ADME) properties of an active drug requires a [email protected] complete understanding of the physicochemical and bio- logical behavior of the drug candidate (3 6). This includes This review provides the reader a concise overview of – the majority of prodrug approaches with the emphasis comprehensive evaluation of drug-likeness involving on the modern approaches to prodrug design. The prediction of ADME properties. These predictions can be chemical approach catalyzed by metabolic enzymes attempted at several levels: in vitro–in vivo using data which is considered as widely used among all other obtained from tissue or recombinant material from human approaches to minimize the undesirable drug physico- and preclinical species, and in silico or computational pre- chemical properties is discussed. Part of this review dictions projecting in vitro or in vivo data, involving the will shed light on the use of molecular orbital methods evaluation of various ADME properties, using computa- such as DFT, semiempirical and ab initio for the design tional approaches such as quantitative structure activity of novel prodrugs.
    [Show full text]
  • The 2013 "Research on Drug Evidence"
    The 2013 “Research on Drug Evidence” Report [From the 17th ICPO / INTERPOL Forensic Science Symposium] Robert F. X. Klein U.S. Department of Justice Drug Enforcement Administration Special Testing and Research Laboratory 22624 Dulles Summit Court Dulles, VA 20166 [[email protected]] ABSTRACT: A reprint of the 2013 “Research on Drug Evidence” Report (a review) is provided. KEYWORDS: INTERPOL, Illicit Drugs, Controlled Substances, Forensic Chemistry. Important Information: Distributed at the 17th ICPO / INTERPOL Forensic Science Symposium, Lyon, France, October 8 - 10, 2013.* Authorized Reprint. Copyright INTERPOL. All rights reserved. May not be reprinted without express permission from INTERPOL. For pertinent background, see: Klein RFX. ICPO / INTERPOL Forensic Science Symposia, 1995 - 2016. “Research on Drug Evidence”. Prefacing Remarks (and a Request for Information). Microgram Journal 2016;13(1-4):1-3. Citations in this report from the Journal of the Clandestine Laboratory Investigating Chemists Association were (and remain) Law Enforcement Restricted. The "General Overview" (Talking Paper) was removed from this reprint (Editor's discretion). This reprint is derived from the original electronic document, and is not an image of the best available hard copy (as was utilized for the 1995 and 1998 reports). For this reason, the pagination in the Proceedings is not retained in this reprint, some minor reformatting was done to eliminate deadspace, and all widow and orphan lines were left as is. [* Due to travel restrictions in effect in late 2013, this report and the associated "General Overview" (Talking Paper) was not actually presented, but rather the report was only distributed to the attendees.] Microgram Journal 2016, Volume 13; Numbers 1-4 511 Research on Drug Evidence January 1, 2010 - June 30, 2013 Presented by: Jeffrey H.
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • Orciprenaline Sulphate (Alupent): Planned Withdrawal from the UK Market Following a Risk-Benefit Analysis
    MHRA PUBLIC ASSESSMENT REPORT Orciprenaline sulphate (Alupent): planned withdrawal from the UK market following a risk-benefit analysis November 2009 Executive summary 2 1. Introduction 3 2. Summary of data 3 2.1 Clinical pharmacology 3 2.2 Efficacy 3 2.3 Safety 4 3. Conclusions 8 4. References 9 5. Glossary 10 1 EXECUTIVE SUMMARY (Please note that this summary is intended to be accessible to all members of the public, including health professionals) Background The Medicines and Healthcare products Regulatory Agency (MHRA) is the government agency responsible for regulating the effectiveness and safety of medicines and medical devices in the UK. We continually review the safety of all medicines in the UK, and inform healthcare professionals and the public of the latest safety updates. In our Public Assessment Reports, we discuss the evidence for a safety issue with a particular drug or drug class, and changes made to the product information for the drug on the basis of this evidence, which will help safeguard public health. This MHRA Public Assessment Report discusses a review of the risks and benefits of a medicine called orciprenaline sulphate. Orciprenaline sulphate is available for oral administration as a syrup used to treat reversible airways obstructiona, which is a symptom of asthmab and chronic obstructive pulmonary diseasec. It acts on specific areas in the body called β- receptors, which relaxes the muscles used for breathing and opens the airways in the lungs. Orciprenaline sulphate was licensed in 1972 and is marketed in the UK under the brand name Alupent Syrup. As with any medicine, the use of orciprenaline sulphate may lead to adverse reactions (side-effects) in some individuals, which are described in the product information, including the patient information leaflet (see the Electronic Medicines Compendium (product information) website).
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • ABC of Poisoning. Emergency Drugs: Agents Used in the Treatment Of
    1984 1AFnT('AT VOT. TmFT 289 22 SEPTEMBER UIQnTCTIT utILtjTOTTRMAT vJV' _- - . _ 742 D.ll.lilm13 4=.-, TIM MEREDITH JANE CAISLEY ABC ofPoisoning GLYN VOLANS EMERGENCY DRUGS: AGENTS USED IN THE TREATMENT OF POISONING A readily available and practical guide to the drugs used in the treatment of / poisoning is important, since many of the agents concerned are used infrequently; some can be obtained only from selected poisons treatment centres, and others, although listed in textbooks, are not available in the United Kingdom; still others are now considered obsolete and, in some cases, actually dangerous. The article Is basen advice Lists ofrecommended drugs have been published by the Department of appendixah artiendixsHto basedcrcularcircuon HNhen(78) Health and Social Security, most recently as HN(62)13 and HN(78)23. DrHuSS s 23 Ougs of Special Value in the1This article is based on these earlier lists, although, necessarily, many more Treatment of Poisoning in drugs have been included and additional information is given on the Accident and Emergency indications for use, mode ofaction, presentation, and dosage. In future this Departments list will be revised as necessary, and copies will be available from the National Poisons Information Service. Agents used for local cleansing, reliefofpain, fluid replacement, oxygen, and the more general care of the injured patient are not included. The need for collaboration and discussion between doctors and pharmacists in the preparation ofthis list is readily apparent and we would welcome comments which may be taken into account in future revisions. (1) Recommended agents that are readily available The decision to stock individual items will depend on the expected ofthe hospital concerned.
    [Show full text]
  • I-16) Urine Drug Testing (Reference Committee K
    REPORT 1 OF THE COUNCIL ON SCIENCE AND PUBLIC HEALTH (I-16) Urine Drug Testing (Reference Committee K) EXECUTIVE SUMMARY Objective. The Council on Science and Public Health initiated this report to help promulgate urine drug testing (UDT) as a medical management tool that can be used to better serve patient populations. Methods. English-language articles were selected from a search of the PubMed database through August 5, 2016 using the search terms “urine drug testing” and “opioids,” and “urine drug testing” and “controlled substances.” Additional articles were identified from a review of the references cited in retrieved publications. Searches of selected medical specialty society websites were conducted to identify clinical guidelines and position statements. Results. Many urine drug tests (UDTs) utilized in clinical care are grounded in immunoassay (IA) technology. IA UDTs are designed to detect a specific drug or a class of drugs as either present or absent based on a designated threshold concentration. Results based on IAs are considered presumptive and are often used as an initial screening test (i.e., qualitatively positive or negative) in clinical UDT. Point-of-care (POC) tests are typically non-instrumented IA devices (strips, dipcards) that can be used in clinics and are presumptive, qualitative, variable, and have a number of other limitations. The current gold standard and method of confirmatory testing after IA in UDT is separation of a specimen and specific identification of drugs/metabolites using gas or liquid chromatography-mass spectrometry (GC-, LC-MS). Recently, liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been utilized, with success, as screening technique.
    [Show full text]
  • Sign up to Receive ATOTW Weekly – Email [email protected]
    Sign up to receive ATOTW weekly – email [email protected] ACCIDENTAL POISONING IN CHILDREN ANAESTHESIA TUTORIAL OF THE WEEK 95 9TH JUNE 2008 Dr Susara Ribbens Specialist Registrar North Central London School of Anaesthetics [email protected] Introduction Poisoning is a significant global public health problem. According to the World Health Organisation data, an estimated 350 000 people died from unintentional poisoning in 2002. Accidental poisoning occurs most often in the age group 1-5 years although less than one per cent of poisoning in children is serious. More than 94% of fatal poisonings occur in low- and middle-income countries. It remains a challenge to identify those at risk at an early stage. Education of the general public and also the provision of child-proof containers for household chemicals and medicines play a key role in prevention. (Toxic plants, insect and snake bites are not discussed in this tutorial, but see www.rch.org.au/poisons for more information) Questions True or false: 1. Emesis or nasogastric aspiration are indicated after sodium hydroxide ingestion. 2. Regarding paraffin ingestion – abnormalities on the chest film may be seen in the absence of symptoms. 3. A fever after paraffin ingestion is always due to a secondary infection. 4. Ingestion of small amounts of paraquat is usually harmless. 5. High FiO2 should be avoided in paraquat ingestion to prevent pulmonary fibrosis. 6. Organophosphate forms an irreversible complex with cholinesterase. 7. Carbon monoxide is irritant with a distinctive odour. 8. The SpO2 reading in carbon monoxide poisoning is usually less than 85%. 9. A plasma paracetamol level should be taken within 2 hours of ingestion.
    [Show full text]